EPO published patent application EP3730131A1 for BPGbio Inc. on March 25, 2026. The patent covers a method of treating brain cancer (A61P 35/00, A61P 35/02 classifications) by continuous infusion of Coenzyme Q10 (A61K 31/122), with various co-formulations including A61K 31/337, A61K 31/513, A61K 31/519, A61K 31/704, A61K 31/7068, and A61K 31/7076. The patent names nine inventors and designates 35 European states including all EU member states, Switzerland, Norway, and Turkey.

Patent publication does not impose compliance obligations on third parties. Companies developing Coenzyme Q10 formulations for oncology applications should review freedom-to-operate implications. Healthcare researchers conducting clinical trials involving continuous CoQ10 infusion for brain tumors may need to consider licensing requirements. This is an informational publication and does not create immediate regulatory requirements.